 post-myocardi infarct mortal patient ventricular prematur depolar canadian amiodaron myocardi infarct arrhythmia trial pilot studi background survivor acut myocardi infarct frequent repetit ventricular prematur depolar vpd ambulatori contribut risk all-caus mortal sudden death beta-block antiarrhythm drug mortal patient vpd pilot studi data aid design multicent trial amiodaron reduct mortal cardiac arrhythmia patient method result seventy-seven patient acut myocardi infarct previou day vpds/hr run ventricular tachycardia electrocardiograph record double-blind fashion amiodarone-to-placebo ratio dose mg/kg/day week mainten dose mg/day reduct interv respons vpd suppress excess plasma level toxic vpd suppress week week amiodaron placebo hormon elev skin reaction side effect amiodaron studi drug side effect noncompli amiodaron patient placebo patient patient maximum year mean month arrhythm death ventricular fibril amiodaron patient placebo patient rate all-caus mortal conclus amiodaron moder load mainten dosag adjust respons plasma level vpd suppress side effect result effect vpd suppress accept level toxic